Item 9 Labs Corp.

PNK:INLB

$0.00035 USD

$0.0 (40.0%)

Volume
28.03M
Average Volume
14.71M
Market Capitalization
$35.83K
P/E Ratio
0.00
Dividend Yield
0.00%
Price Target
$
Year High
$0.18
Year Low
$0.00
Payout Ratio
$0.00
Current Ratio
$0.06

Industry, Sector & symbol

Stock Exchange Other OTC
CEO Mr. Robert E. Mikkelsen
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Current Symbol INLB
CUSIP 46564C203
CIK 0001500123
Web https://www.item9labscorp.com
Phone 833 867 6337
Currency USD
Employees 97
Country US

Liquidity

Debt-to-Equity Ratio 0.65
Payout Ratio 0.00
Current Ratio 0.06
Quick Ratio 0.02
Cash Ratio 0.00

Sales & Book Value

Annual Sales $21.76M
Price / Sales 0.00
Cash Flow -0.03
Price / Cash Flow -0.01
Price / Book 0.00

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Buy
Rating Score(0-5) 4
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.33
Trailing P/E Ratio 0.00
PEG Ratio 0.00
P/E Growth 0.00
Net Income $-31.18M
Net Margin -157.69%
Pretax Margin -157.65%
Return on Equity -53.38%
Return on Assets -27.72%

Financials Score

AltmanZ Score -1.68
Piotroski Score 3.00
Working Capital -55.47M
Total Assets 112.02M
Ebit -10.04M
Market Cap 35.83K
Total Liabilities 59.37M

Poll Results

About Item 9 Labs Corp. (PNK:INLB) Stock

Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona. It also operates and sells medical and adult-use cannabis dispensary franchises under the Unity Rd brand name. Item 9 Labs Corp. is headquartered in Phoenix, Arizona. ...

Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q3 2022 Results - Earnings Call Transcript

2022-08-16 11:53:06

Item 9 Labs Corp. (OTCQX:INLB) Q3 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Jason Assad - Investor Relations Andrew Bowden - Chief Executive Officer Bobby Mikkelsen - Chief Financial Officer Jason Assad [Abrupt Start] Joining me on today's call is our Chief Executive Officer, Andrew Bowden and our Chief Financial Officer, Bobby Mikkelson. Shortly before this call, we filed our Form 10-Q, a copy of which is available on the company's website at item9labscorp.com.

Item 9 Labs Corp. (INLB) Reports Q3 Loss, Misses Revenue Estimates

2022-08-15 21:04:06

Item 9 Labs Corp. (INLB) delivered earnings and revenue surprises of -100% and 29.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Item 9 Labs Corp. to Host Third Quarter Fiscal Year 2022 Earnings Call on August 16 at 8:30 a.m. ET

2022-08-03 10:36:00

PHOENIX , Aug. 3, 2022 /PRNewswire/ -- Item 9 Labs Corp. (OTCQX: INLB) (the "Company")—a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products—announced today that it will host a conference call on Tuesday August 16, 2022, to share financial results for the third quarter of fiscal year 2022, which ended June 30, 2022. The 10Q will be filed on Monday, August 15, 2022.

Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q2 2022 Results - Earnings Call Transcript

2022-05-16 23:25:17

Item 9 Labs Corp. (OTCQX:INLB) Q2 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Jason Assad - Investor Relations Andrew Bowden - Chief Executive Officer Bobby Mikkelsen - Chief Financial Officer Conference Call Participants Jason Assad Hello, this is Jason Assad, Investor Relations with Item 9 Labs. Good afternoon, and welcome to Item 9 Labs Fiscal Q2 2022 Results Conference Call for the three months ended March 31, 2022.

Item 9 Labs Corp. (INLB) Reports Q2 Loss, Lags Revenue Estimates

2022-05-16 20:18:06

Item 9 Labs Corp. (INLB) delivered earnings and revenue surprises of -33.33% and 9.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Frequently Asked Questions

What is the current Item 9 Labs Corp. (INLB) stock price?

Item 9 Labs Corp.(PNK:INLB) stock price is $0.00035 in the last trading session. During the trading session, INLB stock reached the peak price of $4 while $2.9E was the lowest point it dropped to. The percentage change in INLB stock occurred in the recent session was 40.0% while the dollar amount for the price change in INLB stock was $0.0.

INLB's industry and sector of operation?

The PNK listed INLB is part of Drug Manufacturers—Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of INLB?

Mr. Robert E. Mikkelsen | Secretary, Treasurer & Chief Financial Officer
Mr. Mark Busch | Senior Vice President of Corporate Development
Mr. Christopher Leland Wolven | Chief Operating Officer
Mr. Jeffrey I. Rassas | Strategic Advisor & Director
Ms. Jayne Levy | Senior Vice President of Communications

How many employees does INLB have?

Number of INLB employees currently stands at 97. INLB operates from 2727 North 3rd Street, Phoenix, AZ 85004, US.

Link for INLB official website?

Official Website of INLB is: https://www.item9labscorp.com

How do I contact INLB?

INLB could be contacted at phone #833 867 6337 and can also be accessed through its website. INLB operates from 2727 North 3rd Street, Phoenix, AZ 85004, US.

How many shares of INLB are traded daily?

The average number of INLB shares traded daily for last 3 months was 14.71M.

What is the market cap of INLB currently?

The market value of INLB currently stands at $35.83K with its latest stock price at $0.00035